Skip to main content
Premium Trial:

Request an Annual Quote

PCR Pharma Vet Joins Gene Express


There are two big reasons why Nick Lazaridis decided to join Gene Express as the company’s new president: “One is personalized medicine,” he says, “and the other is their technology.” That technology is the company’s StaRT-PCR platform, currently used by many clinical researchers for analysis of tissue, xenografts, and formalin-fixed paraffin embedded samples.

But with more than 18 years in pharmaceutical development, Lazaridis is bringing more than just his enthusiasm to the table. “First, is my relationship with the pharmaceutical industry in terms of product development and my knowledge of the FDA requirements to file acceptable data,” he says. “I also have a very good overall knowledge in terms of Good Manufacturing Practice, and that’s something new to the genomic arena.”

Experience with strict manufacturing standards will be a good fit for a company that touts assays produced under tight manufacturing conditions and its own proprietary standards methods. “I believe Gene Express has the only technology that provides standards and measurable results,” says Lazaridis. “I’m just trying to take the strengths of the technology and internal standards to basically every drug development phase [that] will need StaRT-PCR.”

Prior to Gene Express, Lazaridis spent five years at AAI Pharma, where he served as senior vice president of preclinical operations. Before that, he was senior vice president of laboratory services for AAI Development Services. Through the ’90s, he held several positions at AAI International, including director of analytical and chemical development and vice president of acquisition and integration of pharmaceutical operations.

Lazaridis is hopeful that StaRT-PCR will be a major player in the drug development market further down the road. “In five years, I would like to see our technology be the leading force of [quantifying] any biomarker that is out there.”

— Matthew Dublin

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.